Johnson & Johnson has dropped a pair of CAR-T cell therapies, axing programs it once predicted could deliver peak sales north ...

We also report on a new use for artificial intelligence that could help eliminate some racial inequities in heart disease ...

There has been a swing towards in vivo CAR-T therapies lately, as big pharmas sign acquisition deals and new therapies hit ...

This review examines how CAR-T cell therapy is expanding beyond blood cancers into solid tumors, autoimmune diseases, chronic ...

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular ...

Stem-cell memory T (TSCM) cells are a rare subset of immune cells with the ability to self-renew, persist long term, and ...

Rutgers University researchers find that certain aging immune T cells can blunt cell expansion and may help explain why many ...

Curocell, an immuno-oncology cell therapy developer, has secured approval for RIMQARTO® Inj., South Korea’s first domestically developed CAR-T therapy ...

Single-cell RNA sequencing is giving researchers a clearer view of why some CAR-T cells persist, expand, kill tumors ...

CAR-T cell therapy works well in blood cancers, but many patients still become resistant. A key reason is the presence of CAR ...

Researchers have developed a sensitive CAR-T therapy that targets 'faint' proteins in solid tumors, potentially transforming ...

An early-stage trial indicates that CAR-T therapy using T memory stem cells may enable certain blood cancer patients to avoid pre-treatment chemotherapy. The modified therapy achieved higher complete ...